# Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer

> **NCT00004635** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 159 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Thalidomide
- **DRUG:** leuprolide acetate
- **DRUG:** goserelin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00004635
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-03-01
- **Primary completion:** 2005-01-30
- **Final completion:** 2010-03-30
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2018-05-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004635, "Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00004635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*